Skip to content

Journal of Psychiatry and Neuroscience

ISSN 1180-4882, 1488-2434

16 papers in the library · 131 citations · publishing 2003-2024

Papers

Sort Most recent Most cited

CCNP Innovations in Neuropsychopharmacology Award

Journal of Psychiatry and Neuroscience September 19, 2024 Gabriella Gobbi 7 citations

For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last few years, a renaissance in the use of psychedelic drugs for mental disorders has occurred in Western society; consequently, a pressing scientific need to elucidate the intricate mechanisms underlying their actions has arisen. Psychedelics mainly...

Widespread reductions in cortical thickness following ketamine abuse.

Journal of Psychiatry and Neuroscience 2024 Jinsong Tang, Qiuxia Wu, Chang Qi et al. 7 citations

Esketamine is a version of ketamine that has been approved for treatment-resistant depression, but our previous studies showed a link between non-medical use of ketamine and brain structural and functional alterations, including dorsal prefrontal grey matter reduction among chronic ketamine users. In this study, we sought to determine cortical thickness abnormalities following long-term,...

The amino acid metabolism pathway of peripheral T lymphocytes and ketamine-induced schizophrenia-like phenotype.

Journal of Psychiatry and Neuroscience 2024 Peipei Wang, Linzhi Jiang, Junmei Hu et al. 1 citation

The intricate interplay between peripheral adaptive immune cells and the central nervous system (CNS) has garnered increasing recognition. Given that alterations in cell quantities often translate into modifications in metabolite profiles and that these metabolic changes can potentially traverse the bloodstream and enter the CNS, thereby modulating the progression of mental illnesses, we sought...

DOI: 10.1503/jpn-240038 (opens in new tab) Full text (opens in new tab) Schizophrenia research Amino acid metabolism Immunology Ketamine studies

Mindfulness-based intervention for benzodiazepine deprescription in hemodialysis patients with anxiety and depressive symptoms

Journal of Psychiatry and Neuroscience May 12, 2023 Nicolas Garel, Christina Rigas, Mona Ben M’rad et al. 3 citations

A 35-year-old female hemodialysis (HD) patient with end-stage renal disease was able to successfully withdraw from benzodiazepines, which had been prescribed for managing psychiatric and pain symptoms, following a mindfulness-based stress reduction (MBSR) intervention. The patient, who had been

Distinct and shared therapeutic neural mechanisms of mindfulness-based and social support stress reduction groups in adults with autism spectrum disorder.

Journal of Psychiatry and Neuroscience 2023 Broc A. Pagni, Ethan Hill, Melissa J M Walsh et al. 20 citations

Mindfulness-based stress reduction (MBSR) alleviates depression and anxiety in adults with autism spectrum disorder (ASD); however, underlying therapeutic neural mechanisms and mindfulness-specific effects have yet to be elucidated. We randomly assigned adults with ASD to MBSR or social support/education (SE). They completed questionnaires that assessed depression, anxiety, mindfulness traits,...

Complexities of psychedelics for therapeutic use in obesity and eating disorders

Journal of Psychiatry and Neuroscience October 25, 2022 A. Reichelt

In an interesting and timely editorial, Borgland and Neyens provide a snap­ shot of preclinical research that could support the development of psyche­ delic drugs as part of a therapeutic regimen in individuals with obesity or eating disorders (EDs), including an­ orexia nervosa (AN) and binge eating disorder (BED).1 The role of the sero­ tonergic system in appetite was key in the development...

Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies

Journal of Psychiatry and Neuroscience June 1, 2022 Stephanie L. Borgland, Drew M. Neyens 14 citations

There has been a substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for various psychiatric illnesses, including substance use disorder[1][1],[2][2] and major depressive disorder.[3][3]–[6][4] Classical psychedelics include lysergic acid

Impaired cognitive performance under psychosocial stress in cannabis-dependent men is associated with attenuated precuneus activity

Journal of Psychiatry and Neuroscience February 26, 2020 Weihua Zhao, Kaeli Zimmermann, Xinqi Zhou et al. 14 citations

Background: Deficient regulation of stress plays an important role in the escalation of substance use, addiction and relapse. Accumulating evidence suggests dysregulations in cognitive and reward-related processes and the underlying neural circuitry in cannabis dependence. However, despite the important regulatory role of the endocannabinoid system in the stress response, associations between...

Adolescent THC exposure in female rats leads to cognitive deficits through a mechanism involving chromatin modifications in the prefrontal cortex.

Journal of Psychiatry and Neuroscience March 2018 Pamela Prini, Franceso Rusconi, Erica Zamberletti et al.

Increasing cannabis consumption among adolescents, studies that link its early use with mental illnesses, and the political debate on cannabis legalization together call for an urgent need to study molecular underpinnings of adolescent brain vulnerability. The emerging role of epigenetic mechanisms in psychiatric diseases led us to hypothesize that epigenetic alterations could play a role in...

Mindfulness-based treatments for posttraumatic stress disorder: a review of the treatment literature and neurobiological evidence.

Journal of Psychiatry and Neuroscience October 2, 2017 Jenna E Boyd, Ruth A. Lanius, Margaret C Mckinnon

Mindfulness-based treatments for posttraumatic stress disorder (PTSD) have emerged as promising adjunctive or alternative intervention approaches. A scoping review of the literature on PTSD treatment studies, including approaches such as mindfulness-based stress reduction, mindfulness-based cognitive therapy and metta mindfulness, reveals low attrition with medium to large effect sizes. We...

Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.

Journal of Psychiatry and Neuroscience June 1, 2017 Stephanie Thiebes, Gregor Leicht, Stjepan Curic et al.

Background: Targeting the N-methyl-D-aspartate receptor (NMDAR) is a major translational approach for treating negative symptoms of schizophrenia. Ketamine comprehensively produces schizophrenia-like symptoms, such as positive, cognitive and negative symptoms in healthy volunteers. The amplitude of the mismatch negativity (MMN) is known to be significantly reduced not only in patients with...

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.

Journal of Psychiatry and Neuroscience June 2017 Lily R. Aleksandrova, Anthony G. Phillips, Yu Tian Wang

The molecular mechanisms underlying major depressive disorder remain poorly understood, and current antidepressant treatments have many shortcomings. The recent discovery that a single intravenous infusion of ketamine at a subanesthetic dose had robust, rapid and sustained antidepressant effects in individuals with treatment-resistant depression inspired tremendous interest in investigating the...

Biologic effects of mindfulness meditation: growing insights into neurobiologic aspects of the prevention of depression

Journal of Psychiatry and Neuroscience March 1, 2011 Simon N. Young 23 citations

A recent paper in the Archives of General Psychiatry confirms that mindfulness-based cognitive therapy (MBCT) “offers protection against relapse/recurrence on a par with that of maintenance antidepressant pharmacotherapy.”[1][1] It is a tribute to the accumulated wisdom of humankind that a

Emotional learning during dissociative states in borderline personality disorder.

Journal of Psychiatry and Neuroscience May 1, 2009 U. Ebner-Priemer, Jana Mauchnik, Nikolaus Kleindienst et al.

BACKGROUND Neurobiological findings and clinical data suggest that dissociative experience inhibits conditioning processes, but experimental studies are lacking. The aim of our study was to determine whether high states of dissociative experience would specifically alter emotional learning, but not declarative knowledge. METHODS We used an aversive differential delay conditioning procedure in...

Visual scan paths in first-episode schizophrenia and cannabis-induced psychosis

Journal of Psychiatry and Neuroscience July 1, 2007 Philip J. Benson, Ute Leonards, Robert Lothian et al. 38 citations

OBJECTIVE: Patterns of successive saccades and fixations (scan paths) that are made while viewing images are often spatially restricted in schizophrenia, but the relation with cannabis-induced psychosis has not been examined. We used higher-order statistical methods to examine spatiotemporal characteristics of scan paths to determine whether viewing behaviour was distinguishable on a continuum....

The Psychopharmacology of Herbal Medicine: Plant Drugs That Alter Mind, Brain and Behavior

Journal of Psychiatry and Neuroscience July 1, 2003 Ronald T. Coutts 4 citations

This paperback publication has 428 pages of text, an additional 131 pages of references and an 18-page subject index. The text is organized in 10 chapters, each liberally endowed with relevant figures and tables. The first 3 chapters (72 pages) are very useful because they contain numerous definitions and introduce the reader to neuroscientific and pharmacological topics that appear throughout...

DOI: 10.1139/jpn.0337 (opens in new tab) Psychopharmacology Traditional medicine